Quantitative Systematic Strategies LLC purchased a new stake in shares of Pfizer, Inc. (NYSE:PFE) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 42,897 shares of the biopharmaceutical company’s stock, valued at approximately $1,443,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Asset Planning Services Ltd. grew its stake in shares of Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 137 shares during the period. D. Scott Neal Inc. grew its stake in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Orrstown Financial Services Inc. grew its stake in shares of Pfizer by 23.0% during the 1st quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 612 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new stake in shares of Pfizer during the 1st quarter valued at about $121,000. Finally, Cable Hill Partners LLC grew its stake in shares of Pfizer by 6.0% during the 1st quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 265 shares during the period. Institutional investors and hedge funds own 69.09% of the company’s stock.
In other news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the sale, the insider now directly owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Insiders sold 426,291 shares of company stock worth $14,475,911 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) traded up 0.32% during mid-day trading on Friday, hitting $34.10. The stock had a trading volume of 15,442,446 shares. The firm has a 50 day moving average of $33.36 and a 200-day moving average of $33.49. The stock has a market cap of $202.80 billion, a P/E ratio of 24.95 and a beta of 1.00. Pfizer, Inc. has a one year low of $29.83 and a one year high of $34.75.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.64 earnings per share. Equities research analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.75%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 94.12%.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/09/10/quantitative-systematic-strategies-llc-purchases-shares-of-42897-pfizer-inc-pfe.html.
A number of research analysts recently issued reports on the company. Berenberg Bank reiterated a “hold” rating and set a $36.00 price objective (down from $39.00) on shares of Pfizer in a research note on Tuesday, August 15th. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Thursday, August 24th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Cowen and Company set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Finally, UBS AG reiterated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research note on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $37.61.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.